Perrigo Company plc (PRGO)

Market Cap	1.69B
Revenue (ttm)	4.28B
Net Income (ttm)	-51.80M
Shares Out	137.62M
EPS (ttm)	-0.38
PE Ratio	n/a
Forward PE	4.21
Dividend	$1.16 (9.46%)
Ex-Dividend Date	Nov 28, 2025

Volume	4,047,131
Open	12.81
Previous Close	12.82
Day's Range	12.22 - 12.90
52-Week Range	12.22 - 30.93
Beta	0.36
Analysts	Buy
Price Target	22.50 (+83.52%)
Earnings Date	Nov 5, 2025

About PRGO

Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company offers upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain rel...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Dec 16, 1991
• Employees: 8,379
• Stock Exchange: NYSE
• Ticker Symbol: PRGO
• Website: https://www.perrigo.com

Financial Performance

In 2024, Perrigo Company's revenue was $4.37 billion, a decrease of -6.06% compared to the previous year's $4.66 billion. Losses were -$171.80 million, 1252.8% more than in 2023.

Analyst Summary

According to 4 analysts, the average rating for PRGO stock is "Buy." The 12-month stock price target is $22.5, which is an increase of 83.52% from the latest price.

Price Target

$22.5

(83.52% upside)

Analyst Consensus: Buy